ESMO 2023 BioNTech Data

BioN Tech at ESMO 2023 Modality Program Abstract # Type mRNA BNT116 1503 TiP TiP BNT314 1072P Poster Protein-based therapeutics DB-1305 689P Poster Cell therapies 2 Proffered paper Abstract Title A Phase 2 study of cemiplimab plus BNT116 versus cemiplimab alone in first-line treatment of patients with advanced non-small cell lung cancer with PD-L1 expression ≥50% DuoBody-EpCAM×4-1BB mediates conditional T-cell co-stimulation and promotes antitumor activity in preclinical models DB-1305 (a Trop-2 targeted antibody-drug- conjugate [ADC]) in patients with advanced solid tumors: Preliminary clinical results from the Phase 1/2a study BNT211-01: Interim results from a repeat dose escalation study of CLDN6 CAR-T cells manufactured with an automated process ± a CLDN6-encoding CAR-T cell-Amplifying RNA Vaccine (CARVac) NTC-001: A Phase I study to test safety and efficacy of BNT221, a non-engineered neoantigen-specific T cell product, in patients with advanced or metastatic melanoma Date, Time & Location • Onsite Poster display date • Monday, 23 October 2023 • Session: NSCLC. metastatic • Onsite Poster display date • Monday, 23 October 2023 Session: Investigational Immunotherapy Onsite Poster display date • Monday, 23 October 2023 • Session: Developmental Therapeutics • Mini oral session - Developmental • Monday, 23 October 2023 • 4:30-6 PM CET therapeutics Valencia Auditorium, Hall 10 O Proffered Paper session - Investigational immunotherapy Monday, 23 October 2023 • 10:15-11:40 AM CET Burgos Auditorium, Hall 3 BNT211 LBA35 Mini oral BNT221 10170 BIONTECH

View entire presentation